Literature DB >> 22350803

Sotalol permeability in cultured-cell, rat intestine, and PAMPA system.

Wei Liu1, Hideaki Okochi, Leslie Z Benet, Suo-Di Zhai.   

Abstract

PURPOSE: To clarify sotalol's classification in the BCS versus BDDCS systems through cellular, rat everted sac and PAMPA permeability studies.
METHODS: Studies were carried out in Madin Darby canine kidney (MDCK) and MDR1-transfected MDCK (MDCK-MDR1) cell lines, rat everted gut sacs and the Parallel Artificial Membrane Permeability Assay (PAMPA) system. Three-hour transport studies were conducted in MDCK cell lines (with apical pH changes) and MDCK-MDR1 cells (with and without the P-glycoprotein inhibitor GG918); male Sprague-Dawley rats (300~350 g) were used to prepare everted sacs. In the PAMPA studies, drug solutions at different pH's were dosed in each well and incubated for 5 h. Samples were measured by LC-MS/MS, or liquid scintillation counting and apparent permeability (P(app)) was calculated.
RESULTS: Sotalol showed low permeability in all of the cultured-cell lines, everted sacs and PAMPA systems. It might be a border line P-glycoprotein substrate. The PAMPA study showed that sotalol's permeability increased with a higher apical pH, while much less change was found in MDCK cells.
CONCLUSION: The low permeability rate for sotalol correlates with its Class 3 BDDCS assignment and lack of in vivo metabolism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350803      PMCID: PMC4167886          DOI: 10.1007/s11095-012-0699-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

Review 2.  Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.

Authors:  Chi-Yuan Wu; Leslie Z Benet
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

3.  The use of BDDCS in classifying the permeability of marketed drugs.

Authors:  Leslie Z Benet; Gordon L Amidon; Dirk M Barends; Hans Lennernäs; James E Polli; Vinod P Shah; Salomon A Stavchansky; Lawrence X Yu
Journal:  Pharm Res       Date:  2008-01-31       Impact factor: 4.200

4.  A novel design of artificial membrane for improving the PAMPA model.

Authors:  Xiaoxi Chen; Anthony Murawski; Karishma Patel; Charles L Crespi; Praveen V Balimane
Journal:  Pharm Res       Date:  2008-01-10       Impact factor: 4.200

5.  The BCS, BDDCS, and regulatory guidances.

Authors:  Mei-Ling Chen; Gordon L Amidon; Leslie Z Benet; Hans Lennernas; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

6.  Drug transfer across rat intestinal musculature after edetic acid treatment.

Authors:  R K Nayak; L Z Benet
Journal:  J Pharm Sci       Date:  1971-10       Impact factor: 3.534

7.  Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs.

Authors:  Oliver Thews; Birgit Gassner; Debra K Kelleher; Gerald Schwerdt; Michael Gekle
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

8.  Rational use of in vitro P-glycoprotein assays in drug discovery.

Authors:  J W Polli; S A Wring; J E Humphreys; L Huang; J B Morgan; L O Webster; C S Serabjit-Singh
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

9.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

10.  Biopharmaceutical characterization of sotalol-containing oral immediate release drug products.

Authors:  Axel Alt; Henrike Potthast; Juergen Moessinger; Barbara Sickmüller; Helga Oeser
Journal:  Eur J Pharm Biopharm       Date:  2004-07       Impact factor: 5.571

View more
  6 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion.

Authors:  Yi Zheng; Leslie Z Benet; Hideaki Okochi; Xijing Chen
Journal:  Pharm Res       Date:  2015-02-19       Impact factor: 4.200

3.  Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.

Authors:  Angela Villiger; Cordula Stillhart; Neil Parrott; Martin Kuentz
Journal:  AAPS J       Date:  2016-04-08       Impact factor: 4.009

4.  Mechanistic Insights into Passive Membrane Permeability of Drug-like Molecules from a Weighted Ensemble of Trajectories.

Authors:  She Zhang; Jeff P Thompson; Junchao Xia; Anthony T Bogetti; Forrest York; A Geoffrey Skillman; Lillian T Chong; David N LeBard
Journal:  J Chem Inf Model       Date:  2022-04-14       Impact factor: 6.162

5.  Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations.

Authors:  Kevin R DeMarco; Slava Bekker; Colleen E Clancy; Sergei Y Noskov; Igor Vorobyov
Journal:  Front Pharmacol       Date:  2018-02-01       Impact factor: 5.810

6.  Pharmaceutical and Safety Profile Evaluation of Novel Selenocompounds with Noteworthy Anticancer Activity.

Authors:  Małgorzata Anna Marć; Enrique Domínguez-Álvarez; Gniewomir Latacz; Agata Doroz-Płonka; Carmen Sanmartín; Gabriella Spengler; Jadwiga Handzlik
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.